12 completed, 8 terminated, 5 unknown, 3 active not recruiting. 25 Phase 1, 11 Phase 2, 2 Early Phase 1, 1 Not applicable.
Follow efineptakin alfa: new trials by email Literature Review of efineptakin alfa trials Research Report on efineptakin alfa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) NT-I7, Placebo - Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Recruiting | Washington University School of Medicine | 52 | 2026-06-05 | 2026-10-15 |
| NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NT-I7, CAR T-cell therapy - Large B-cell Lymphoma | Phase 1 | Recruiting | Washington University School of Medicine | 24 | 2026-03-12 | 2026-09-29 |
| Vaccine Response With NT-I7 Recombinant human IL-7-hyFc (NT-I7), Vaccine sequence 1, Vaccine sequence 2 - Breast Carcinoma, Colorectal Adenocarcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2023-05-30 | 2023-11-02 | |
| Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma Biospecimen Collection, Efineptakin alfa, Pembrolizumab - High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Active not recruiting | Mayo Clinic | 53 | 2023-01-24 | 2026-10-05 |
| Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. SL-T10, GX-I7, Pembrolizumab - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Unknown | SL VAXiGEN | 78 | 2022-10-17 | 2024-04-03 |
| NT-I7 for Kaposi Sarcoma in Patients With or Without HIV Efineptakin alfa - AIDS-Related Kaposi Sarcoma, HIV Infection | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 8 | 2022-05-23 | 2024-06-27 |
| Trial of the Combination of GX-188E Vaccination, GX-I7 and Pembrolizumab in Patients With Advanced, Resectable HPV Type 16 and/or 18 Positive Head and Neck Cancer GX-188E, GX-I7, Pembrolizumab, GX-188E, Pembrolizumab, GX-188E, GX-I7 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Yonsei University | 56 | 2022-03-01 | 2026-02-09 |
| GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients GX-I7, Bevacizumab - Recurrent Glioblastoma | Phase 2 | Unknown | Genexine, Inc. | 20 | 2022-01-26 | 2023-06-12 |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC efineptakin alfa, Atezolizumab - Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Terminated | NeoImmuneTech | 33 | 2021-11-15 | 2026-06-11 |
| Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19) NT-I7, Placebo, Blood for research purposes - COVID-19, SARS-CoV-2 | Phase 1 | Withdrawn | Washington University School of Medicine | 2021-07-31 | 2021-08-05 | |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy NT-I7 - Progressive Multifocal Leukoencephalopathy | Early Phase 1 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 12 | 2021-05-05 | 2025-11-18 |
| Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19 GX-I7, GX-I7 vehicle - Covid19 | Phase 1 | Terminated | Genexine, Inc. | 10 | 2021-03-24 | 2022-11-30 |
| NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery Efineptakin alfa - Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Terminated | Hyunseok Kang, MD | 4 | 2021-03-12 | 2025-02-14 |
| NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma NT-I7, Nivolumab - Gastric or Gastro-esophageal Junction (GEJ) or Esophageal Adenocarcinoma (EAC) | Phase 1 | Terminated | NeoImmuneTech | 10 | 2021-01-21 | 2024-08-16 |
| A Trial of NT-I7 in COVID-19 (SPESELPIS) Double-Blind NT-I7, Double-Blind Placebo - COVID-19 | Phase 1 | Terminated | NeoImmuneTech | 7 | 2020-11-27 | 2023-07-14 |
| A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19 GX-I7 - Covid19 | Phase 2 | Unknown | PT Kalbe Genexine Biologics | 210 | 2020-11-01 | 2021-03-24 |
| NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors NT-I7, pembrolizumab (KEYTRUDA®) - Any Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | NeoImmuneTech | 215 | 2020-06-10 | 2026-03-09 |
| High-Risk Skin Cancers With Atezolizumab Plus NT-I7 NT-I7, atezolizumab - Melanoma, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | NeoImmuneTech | 31 | 2019-12-26 | 2025-10-22 |
| Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma GX-I7, Placebo - Newly Diagnosed Glioblastoma | Phase 1 / Phase 2 | Withdrawn | Genexine, Inc. | 2019-08-22 | 2022-03-17 |
Showing 20 of 34. Sign in to see all of them.
COVID-19 (4) · Glioblastoma (3) · Glioma (3) · Lymphopenia (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · HIV Infections (2) · Melanoma (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Triple Negative Breast Neoplasms (2) · AIDS-related Kaposi sarcoma (1) · Carcinoma (1) · Carcinoma, Merkel Cell (1)
Genexine, Inc. (10) · NeoImmuneTech (6) · Washington University School of Medicine (4) · National Cancer Institute (NCI) (2) · Cytheris SA (1) · Cytheris, Inc. (1) · Fred Hutchinson Cancer Center (1) · Hyunseok Kang, MD (1) · Mayo Clinic (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · PT Kalbe Genexine Biologics (1) · SL VAXiGEN (1) · Seoul National University Hospital (1) · Seoul St. Mary's Hospital (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (18) · South Korea (14) · Canada (1) · France (1) · Indonesia (1) · Italy (1) · Poland (1)
Minkyu Heo (3) · Brian Gastman, MD (1) · Chang Wook Jeong, MD, phD (1) · Cheol Kwak, MD, phD (1) · Donghoon Choi, PhD (1) · Howard Lee, M.D, Ph.D. (1) · Hye Ryun Kim (1) · Hyunseok Kang, MD (1) · Irene CM Cortese, M.D. (1) · Irini Sereti (1) · Jae Kwan Lee, MD, PhD (1) · Jian Campian, M.D., Ph.D. (1) · Jian L Campian, MD, PhD (1) · Jian L. Campian, MD, PhD (1)
PMID 42012895, PMID 23012326, PMID 32339447, PMID 35031547, PMID 39915263, PMID 40490502
R01CA286488 (1), R01CA288862 (1), UM1CA137443 (1), UM1CA154967 (1)